MPI Research has announced that it will be collaborating with Kineta. MPI Research will assist Kineta with advancing their autoimmune drug development program. The company said that the collaboration will enable phase one human trials to begin in 2010.
Tina Rogers, director of research and executive vice president of MPI Research, said: “We have a team of scientists knowledgeable about autoimmune diseases and we are eager to collaborate with Kineta on their novel drug development program.”
Charles Magness, president and CEO of Kineta, said: “Partnering with a such as MPI Research allows Kineta to creatively advance our program, accelerating progress of our lead autoimmune drug into man. We look forward to a strong collaboration focused on shared goals.”